(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Sponsor: Blueprint Medicines Corporation
Listed as NCT03580655, this observational or N/A phase trial focuses on Advanced Systemic Mastocytosis and Aggressive Systemic Mastocytosis and remains completed. Sponsored by Blueprint Medicines Corporation, it has been updated 23 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
23 versions recorded-
Apr 28, 2026 — Present [daily]
Completed
Phase: PHASE2 → None
-
Sep 2025 — Apr 2026 [monthly]
Completed PHASE2
-
May 2025 — Sep 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — May 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 18 earlier versions
-
Sep 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2022 — Sep 2023 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Jul 2020 — Sep 2020 [monthly]
Recruiting PHASE2
-
Mar 2020 — Jul 2020 [monthly]
Recruiting PHASE2
-
Jan 2020 — Mar 2020 [monthly]
Recruiting PHASE2
-
Dec 2019 — Jan 2020 [monthly]
Recruiting PHASE2
-
Oct 2019 — Dec 2019 [monthly]
Recruiting PHASE2
-
Sep 2019 — Oct 2019 [monthly]
Recruiting PHASE2
-
Aug 2019 — Sep 2019 [monthly]
Recruiting PHASE2
-
Jul 2019 — Aug 2019 [monthly]
Recruiting PHASE2
-
May 2019 — Jul 2019 [monthly]
Recruiting PHASE2
-
Jan 2019 — May 2019 [monthly]
Recruiting PHASE2
-
Dec 2018 — Jan 2019 [monthly]
Recruiting PHASE2
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2018 — Nov 2018 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2018 — Sep 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
This is an open-label, single arm, Phase 2 study evaluating the efficacy and safety of avapritinib (BLU-285) in patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive SM (ASM), SM with associated hematologic neoplasm (SM-AHN), and mast cell leukemia (MCL)
Contact Information
- Blueprint Medicines Corporation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Ann Arbor, United States , Boston, United States , Buffalo, United States , Chicago, United States , Florence, Italy , Gdansk, Poland , Glasgow, United Kingdom , Groningen, Netherlands , Hamburg, Germany and 22 more locations